title: Technical Advances of the Recombinant Antibody Microarray Technology Platform for Clinical Immunoproteomics.
abstract: In the quest for deciphering disease-associated biomarkers, high-performing tools for multiplexed protein expression profiling of crude clinical samples will be crucial. Affinity proteomics, mainly represented by antibody-based microarrays, have during recent years been established as a proteomic tool providing unique opportunities for parallelized protein expression profiling. But despite the progress, several main technical features and assay procedures remains to be (fully) resolved. Among these issues, the handling of protein microarray data, i.e. the biostatistics parts, is one of the key features to solve. In this study, we have therefore further optimized, validated, and standardized our in-house designed recombinant antibody microarray technology platform. To this end, we addressed the main remaining technical issues (e.g. antibody quality, array production, sample labelling, and selected assay conditions) and most importantly key biostatistics subjects (e.g. array data pre-processing and biomarker panel condensation). This represents one of the first antibody array studies in which these key biostatistics subjects have been studied in detail. Here, we thus present the next generation of the recombinant antibody microarray technology platform designed for clinical immunoproteomics.
authors.affiliation: Department of Immunotechnology and CREATE Health, Lund University, Medicon Village, Lund, Sweden.
authors.forename: Payam
authors.initials: P
authors.lastname: Delfani
authors.affiliation: Department of Immunotechnology and CREATE Health, Lund University, Medicon Village, Lund, Sweden.|Immunovia AB, Lund, Sweden.
authors.forename: Linda
authors.initials: L
authors.lastname: Dexlin Mellby
authors.affiliation: Immunovia AB, Lund, Sweden.
authors.forename: Malin
authors.initials: M
authors.lastname: Nordström
authors.affiliation: Immunovia AB, Lund, Sweden.
authors.forename: Andreas
authors.initials: A
authors.lastname: Holmér
authors.affiliation: Computational Biology & Biological Physics, Department of Astronomy and Theoretical Physics, Lund University, Lund, Sweden.
authors.forename: Mattias
authors.initials: M
authors.lastname: Ohlsson
authors.affiliation: Department of Immunotechnology and CREATE Health, Lund University, Medicon Village, Lund, Sweden.
authors.forename: Carl A K
authors.initials: CA
authors.lastname: Borrebaeck
authors.affiliation: Department of Immunotechnology and CREATE Health, Lund University, Medicon Village, Lund, Sweden.
authors.forename: Christer
authors.initials: C
authors.lastname: Wingren
mesh_terms: D000906:Antibodies / Q000276:immunology; D015415:Biomarkers / Q000032:analysis; D056808:Biostatistics; D057166:High-Throughput Screening Assays / Q000379:methods / Q000592:standards / Q000706:statistics & numerical data; D006801:Humans; D055261:Immunogenetic Phenomena; D040081:Protein Array Analysis / Q000379:methods* / Q000592:standards / Q000706:statistics & numerical data; D040901:Proteomics / Q000379:methods* / Q000592:standards / Q000706:statistics & numerical data; D011786:Quality Control; D011994:Recombinant Proteins / Q000276:immunology
chemical_list: D000906:Antibodies; D015415:Biomarkers; D011994:Recombinant Proteins